Margaret E Gatti-Mays1,2, Fatima H Karzai3, Sanaz N Soltani2, Alexandra Zimmer2, Jeffrey E Green4, Min-Jung Lee5, Jane B Trepel5, Akira Yuno5, Stanley Lipkowitz2, Jayakumar Nair2, Ann McCoy2, Jung-Min Lee2. 1. Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 2. Women's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 3. Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 4. Laboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 5. Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
LESSONS LEARNED: Monotherapy with prexasertib demonstrated modest activity in BRCA wild-type, recurrent triple-negative breast cancer, highlighting the unmet need for combination treatment strategies. Neutropenia, anemia, and thrombocytopenia are common with the use of prexasertib but are manageable with supportive care measures. Prophylactic use of granulocyte colony stimulating factor should be considered to avoid dose reductions or treatment delays. Pharmacodynamic studies showed prexasertib treatment induced DNA damage in peripheral immune cells. BACKGROUND: Cell cycle checkpoint kinase 1 (CHK1) is a major G2/M cell cycle regulator in tumors with p53 dysfunction, such as triple-negative breast cancer (TNBC). We hypothesized the second-generation CHK1 inhibitor, prexasertib, would yield clinical activity in sporadic TNBC. METHODS: This single arm, phase II trial evaluated prexasertib at 105 mg/m2 IV every 2 weeks in patients with metastatic/recurrent TNBC. The primary endpoint was overall response rate (ORR). RESULTS: All nine patients enrolled were germline BRCA wild-type (BRCAwt) and had at least one prior treatment. One partial response (PR) was observed (ORR of 11.1%). Four patients experienced stable disease. The median progression-free survival (PFS) was 86 days (range 17 to 159 days). Grade 3/4 treatment-related adverse events included afebrile neutropenia (n = 8; 88.9%), anemia (n = 3; 33.3%), and thrombocytopenia (n = 1; 11.1%). Pharmacodynamic studies showed prexasertib treatment induced DNA damage in peripheral immune cells and demonstrated a decrease in activated/reinvigorated CD8 T cells; however, the one patient with a PR showed evidence of T-cell recovery. CONCLUSION: Prexasertib monotherapy had modest clinical efficacy in BRCAwt TNBC. Further studies of prexasertib in combination with other agents are needed. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.
LESSONS LEARNED: Monotherapy with prexasertib demonstrated modest activity in BRCA wild-type, recurrent triple-negative breast cancer, highlighting the unmet need for combination treatment strategies. Neutropenia, anemia, and thrombocytopenia are common with the use of prexasertib but are manageable with supportive care measures. Prophylactic use of granulocyte colony stimulating factor should be considered to avoid dose reductions or treatment delays. Pharmacodynamic studies showed prexasertib treatment induced DNA damage in peripheral immune cells. BACKGROUND: Cell cycle checkpoint kinase 1 (CHK1) is a major G2/M cell cycle regulator in tumors with p53dysfunction, such as triple-negative breast cancer (TNBC). We hypothesized the second-generation CHK1 inhibitor, prexasertib, would yield clinical activity in sporadic TNBC. METHODS: This single arm, phase II trial evaluated prexasertib at 105 mg/m2 IV every 2 weeks in patients with metastatic/recurrent TNBC. The primary endpoint was overall response rate (ORR). RESULTS: All nine patients enrolled were germline BRCA wild-type (BRCAwt) and had at least one prior treatment. One partial response (PR) was observed (ORR of 11.1%). Four patients experienced stable disease. The median progression-free survival (PFS) was 86 days (range 17 to 159 days). Grade 3/4 treatment-related adverse events included afebrile neutropenia (n = 8; 88.9%), anemia (n = 3; 33.3%), and thrombocytopenia (n = 1; 11.1%). Pharmacodynamic studies showed prexasertib treatment induced DNA damage in peripheral immune cells and demonstrated a decrease in activated/reinvigorated CD8 T cells; however, the one patient with a PR showed evidence of T-cell recovery. CONCLUSION:Prexasertib monotherapy had modest clinical efficacy in BRCAwt TNBC. Further studies of prexasertib in combination with other agents are needed. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Caitlin D Lowery; Michele Dowless; Matthew Renschler; Wayne Blosser; Alle B VanWye; Jennifer R Stephens; Philip W Iversen; Aimee Bence Lin; Richard P Beckmann; Kateryna Krytska; Kristina A Cole; John M Maris; Douglas S Hawkins; Brian P Rubin; Raushan T Kurmasheva; Peter J Houghton; Richard Gorlick; E Anders Kolb; Min H Kang; C Patrick Reynolds; Stephen W Erickson; Beverly A Teicher; Malcolm A Smith; Louis F Stancato Journal: Clin Cancer Res Date: 2018-12-18 Impact factor: 12.531
Authors: Aditya Bardia; Ingrid A Mayer; Linda T Vahdat; Sara M Tolaney; Steven J Isakoff; Jennifer R Diamond; Joyce O'Shaughnessy; Rebecca L Moroose; Alessandro D Santin; Vandana G Abramson; Nikita C Shah; Hope S Rugo; David M Goldenberg; Ala M Sweidan; Robert Iannone; Sarah Washkowitz; Robert M Sharkey; William A Wegener; Kevin Kalinsky Journal: N Engl J Med Date: 2019-02-21 Impact factor: 91.245
Authors: Alexander C Huang; Michael A Postow; Robert J Orlowski; Rosemarie Mick; Bertram Bengsch; Sasikanth Manne; Wei Xu; Shannon Harmon; Josephine R Giles; Brandon Wenz; Matthew Adamow; Deborah Kuk; Katherine S Panageas; Cristina Carrera; Phillip Wong; Felix Quagliarello; Bradley Wubbenhorst; Kurt D'Andrea; Kristen E Pauken; Ramin S Herati; Ryan P Staupe; Jason M Schenkel; Suzanne McGettigan; Shawn Kothari; Sangeeth M George; Robert H Vonderheide; Ravi K Amaravadi; Giorgos C Karakousis; Lynn M Schuchter; Xiaowei Xu; Katherine L Nathanson; Jedd D Wolchok; Tara C Gangadhar; E John Wherry Journal: Nature Date: 2017-04-10 Impact factor: 49.962
Authors: Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: N Engl J Med Date: 2018-10-20 Impact factor: 91.245
Authors: David Hong; Jeffrey Infante; Filip Janku; Suzanne Jones; Ly M Nguyen; Howard Burris; Aung Naing; Todd M Bauer; Sarina Piha-Paul; Faye M Johnson; Razelle Kurzrock; Lisa Golden; Scott Hynes; Ji Lin; Aimee Bence Lin; Johanna Bendell Journal: J Clin Oncol Date: 2016-04-04 Impact factor: 44.544
Authors: Anish Thomas; Christophe E Redon; Linda Sciuto; Emerson Padiernos; Jiuping Ji; Min-Jung Lee; Akira Yuno; Sunmin Lee; Yiping Zhang; Lan Tran; William Yutzy; Arun Rajan; Udayan Guha; Haobin Chen; Raffit Hassan; Christine C Alewine; Eva Szabo; Susan E Bates; Robert J Kinders; Seth M Steinberg; James H Doroshow; Mirit I Aladjem; Jane B Trepel; Yves Pommier Journal: J Clin Oncol Date: 2017-12-18 Impact factor: 50.717
Authors: Fatima Karzai; David VanderWeele; Ravi A Madan; Helen Owens; Lisa M Cordes; Amy Hankin; Anna Couvillon; Erin Nichols; Marijo Bilusic; Michael L Beshiri; Kathleen Kelly; Venkatesh Krishnasamy; Sunmin Lee; Min-Jung Lee; Akira Yuno; Jane B Trepel; Maria J Merino; Ryan Dittamore; Jennifer Marté; Renee N Donahue; Jeffrey Schlom; Keith J Killian; Paul S Meltzer; Seth M Steinberg; James L Gulley; Jung-Min Lee; William L Dahut Journal: J Immunother Cancer Date: 2018-12-04 Impact factor: 13.751
Authors: Kevin J Lee; Griffin Wright; Hannah Bryant; Leigh Ann Wiggins; Michele Schuler; Natalie R Gassman Journal: Cancer Drug Resist Date: 2020-12-05